|
US2021113513A1
|
|
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US2020261391A1
|
|
Methods of reducing the risk of a cardiovascular event in a statin-treated subject by increasing serum and plasma epa and dpa levels
|
|
WO2020065402A1
|
|
Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution
|
|
AU2019321568A1
|
|
Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
|
|
CN111991386A
|
|
Method of reducing the risk of a cardiovascular event in a subject
|
|
US2020093777A1
|
|
Methods of reducing the risk of cardiovascular events in a subject
|
|
CN112218630A
|
|
Method of reducing the risk of a cardiovascular event in a subject
|
|
CA3042062A1
|
|
Methods of reducing the risk of cardiovascular events in a subject
|
|
US2019275057A1
|
|
Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
|
|
US2019269642A1
|
|
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hscrp levels of at least about 2 mg/l
|
|
US2019209506A1
|
|
Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
|
|
US2019054054A1
|
|
Methods reducing or preventing oxidation of high density lipoprotein (HDL)
|
|
US2019054058A1
|
|
Methods of Treating or Preventing Bone Loss
|
|
US2018333383A1
|
|
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US2017333377A1
|
|
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
AU2016231552A1
|
|
Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
|
|
US2017151202A1
|
|
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
AU2016219657A1
|
|
Stable pharmaceutical composition and methods of using same
|
|
AU2016203375A1
|
|
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
WO2016140949A1
|
|
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
